<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707508</url>
  </required_header>
  <id_info>
    <org_study_id>Y_106_0298</org_study_id>
    <nct_id>NCT04707508</nct_id>
  </id_info>
  <brief_title>Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus</brief_title>
  <official_title>Investigating the Effect of Renin-Angiotensin System Inhibitors in Addition to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Prospective Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantou Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantou Christian Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder in which a substantial&#xD;
      number of patients cannot attain treatment target despite antidiabetic drugs. The&#xD;
      renin-angiotensin system (RAS) has recently been implicated in the development of insulin&#xD;
      resistance and impaired glucose metabolism. This study investigates the effect of adding RAS&#xD;
      inhibitors to standard antidiabetic therapy in patients with T2DM. The primary outcome&#xD;
      measure is the change in serum glycosylated hemoglobin A1c after 24 weeks of treatment.&#xD;
      Secondary outcomes measures include changes in plasma lipid profile and blood pressure after&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">November 29, 2019</completion_date>
  <primary_completion_date type="Actual">January 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum glycosylated hemoglobin A1c</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in serum glycosylated hemoglobin A1c of the participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma lipid fractions</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in plasma triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in systolic blood pressure and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Valsartan and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 80 mg and metformin</intervention_name>
    <description>Valsartan 80 mg once daily in addition to metformin monotherapy</description>
    <arm_group_label>Valsartan and metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin monotherapy</description>
    <arm_group_label>Metformin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults over 21 years of age&#xD;
&#xD;
          -  clinically diagnosed type 2 diabetes mellitus&#xD;
&#xD;
          -  recipients of metformin monotherapy&#xD;
&#xD;
          -  compliance with prescriptions and dietary intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  recipients of any second-line antidiabetic drug in addition to metformin&#xD;
&#xD;
          -  recipients of any antihypertensive medication before study enrollment&#xD;
&#xD;
          -  hemoglobin disorders&#xD;
&#xD;
          -  chronic kidney disease&#xD;
&#xD;
          -  thyroid dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po-Chung Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantou Christian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantou Christian Hospital</name>
      <address>
        <city>Nantou City</city>
        <state>Nantou County</state>
        <zip>540001</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi: 10.2991/jegh.k.191028.001.</citation>
    <PMID>32175717</PMID>
  </reference>
  <reference>
    <citation>Nehme A, Zouein FA, Zayeri ZD, Zibara K. An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J Cardiovasc Dev Dis. 2019 Mar 29;6(2). pii: E14. doi: 10.3390/jcdd6020014. Review.</citation>
    <PMID>30934934</PMID>
  </reference>
  <reference>
    <citation>Joseph JJ, Echouffo Tcheugui JB, Effoe VS, Hsueh WA, Allison MA, Golden SH. Renin-Angiotensin-Aldosterone System, Glucose Metabolism and Incident Type 2 Diabetes Mellitus: MESA. J Am Heart Assoc. 2018 Sep 4;7(17):e009890. doi: 10.1161/JAHA.118.009890.</citation>
    <PMID>30371168</PMID>
  </reference>
  <reference>
    <citation>Das UN. Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome. J Transl Int Med. 2016 Jun 1;4(2):66-72. doi: 10.1515/jtim-2016-0022. Epub 2016 Jul 7.</citation>
    <PMID>28191524</PMID>
  </reference>
  <reference>
    <citation>Mor A, Aizman E, George J, Kloog Y. Ras inhibition induces insulin sensitivity and glucose uptake. PLoS One. 2011;6(6):e21712. doi: 10.1371/journal.pone.0021712. Epub 2011 Jun 29.</citation>
    <PMID>21738773</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nantou Christian Hospital</investigator_affiliation>
    <investigator_full_name>Po-Chung Cheng</investigator_full_name>
    <investigator_title>Director, Division of endocrine and metabolic diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

